Article Text

Download PDFPDF
Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1)
  1. Belinda R Lennox1,2,
  2. Giuliano Tomei1,2,
  3. Sally-Anne Vincent1,2,
  4. Ksenija Yeeles1,2,
  5. Rebecca Pollard1,2,
  6. Emma Palmer-Cooper1,
  7. Peter Jones3,
  8. Michael S Zandi4,
  9. Alasdair Coles5
  1. 1 Department of Psychiatry, University of Oxford, Oxford, UK
  2. 2 Oxford Health NHS Foundation Trust, Oxford, UK
  3. 3 Department of Psychiatry, University of Cambridge, NIHR Cambridge Biomedical Research Centre, Cambridge, UK
  4. 4 Department of Molecular Neuroscience and UCLH Biomedical Research Centre, University College London, London, UK
  5. 5 Department of Clinical Neurosciences, University of Cambridge, NIHR Cambridge Biomedical Research Centre, Cambridge, UK
  1. Correspondence to Dr Belinda R Lennox, Department of Psychiatry, University of Oxford, Warneford Hospital, Headington, Oxford, OX37JX, UK; belinda.lennox{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Antibodies against N-methyl D-aspartate receptor (NMDAR) and other neuronal cell surface targets are recognised associations of immunotherapy-responsive autoimmune encephalitis. Initially, patients present with symptoms of behavioural change and psychosis, often subsequently developing seizures and cognitive impairment, rapidly progressing over a few weeks to develop a life-threatening combination of autonomic instability and loss of consciousness.1

There is in vitro and in vivo evidence that these antibodies are pathogenic and directly cause encephalitis. Although never formally demonstrated in a controlled trial, open label clinical studies show that patients receiving immunotherapy, such as intravenous immunoglobulins (IVIG) or plasma exchange (PLEX) with or without corticosteroids, have better recovery and reduced relapse rates. Therefore, clinical consensus guidelines recommend that immunotherapy should be given as soon as possible after diagnosis.2

Several studies have assessed the prevalence of these antibodies in purely psychiatric presentations. NMDAR antibodies are the most commonly identified; in some studies, these are twice as prevalent in patients with early psychosis than in healthy controls, being seen at rates of between 4% and 12% of cases (OR 2.70, 95% CI 1.11 to 6.56).3 We have seen a number of such cases which respond to immunotherapy in an uncontrolled study.4 We have therefore proposed a randomised, placebo-controlled trial of immunotherapy in psychosis associated with antineuronal antibodies, to inform clinical practice and to advance understanding of the …

View Full Text


  • Contributors BL, PBJ, MSZ and AJC designed the study. All authors contributed to data collection, analysis and interpretation. All authors have approved the final version of the manuscript and are accountable for the accuracy and integrity of the data.

  • Funding The study was funded by The Stanley Medical Research Institute (14T-004).

  • Competing interests None declared.

  • Patient consent Parental/guardian consent obtained.

  • Ethics approval South Central – Oxford C Research Ethics Committee (REC reference 15/SC/0219).

  • Provenance and peer review Not commissioned; externally peer reviewed.